Sitka Biopharma Announces New Investment from Global Health Sciences Fund
Summary
A spin-off of CDRD and the University of British Columbia (UBC), Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Dr. Michael Parr, Sitka’s President and Chief Scientific Officer said, “ This is an extremely pivotal investment for Sitka as it means we can complete the final IND-enabling studies and take our lead therapeutic for bladder cancer into the clinic via our partnership with CRUK. This investment sets up the company for rapid progression through those initial clinical trials and we can also begin planning to expand STK-01 to additional indications.” Ms. Karimah Es Sabar, Chief Executive Officer of Quark Venture and Director of GHS Fund commented “ GHS Fund believes Sitka is poised for an important medical breakthrough in bladder cancer. Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Our strategic goal is to continually support such entrepreneurial biotechnology companies to efficiently improve the technology platform and obtain high-growth value by providing diversified healthcare products or services.